PHARMASCROLL
enquiry@pharmascroll.com Mail Us
  • Home
  • About Us
    • Mission and Vision
    • Our Team
    • Why PharmaScroll
  • Business Intelligence
    • TreasureTell
  • Social Media Analytics
    • SocialBI
  • Market Research Services
  • Newsroom
    • Blog
    • Podcast
    • Press Release
    • Recent News
      • Neuroscience
        • Migraine
        • Multiple Sclerosis
        • Alzheimer’s
        • Parkinson’s
        • Epilepsy
        • Schizophrenia
        • Depression
        • ADHD
      • Respiratory
        • COPD
        • Asthma
        • Pulmonary Fibrosis
        • Cystic fibrosis
        • Rhinitis
      • Oncology
      • Diabetes
  • Careers
  • Contact Us
PHARMASCROLL
  • Home
  • About Us
    • Mission and Vision
    • Our Team
    • Why PharmaScroll
  • Business Intelligence
    • TreasureTell
  • Social Media Analytics
    • SocialBI
  • Market Research Services
  • Newsroom
    • Blog
    • Podcast
    • Press Release
    • Recent News
      • Neuroscience
        • Migraine
        • Multiple Sclerosis
        • Alzheimer’s
        • Parkinson’s
        • Epilepsy
        • Schizophrenia
        • Depression
        • ADHD
      • Respiratory
        • COPD
        • Asthma
        • Pulmonary Fibrosis
        • Cystic fibrosis
        • Rhinitis
      • Oncology
      • Diabetes
  • Careers
  • Contact Us
enquiry@pharmascroll.com Mail Us
HomeNewsNeuroscienceParkinson's
  • FDA expediates approval process for Voyager’s Parkinson’s drug by granting RMAT designation

    • June 25, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • Bacteriophages might be a potential cause of Parkinson’s disease, research finds

    • June 12, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • Oxford BioMedica & Axovant Sciences sign a $842.5 Mn deal for Parkinson’s Drug

    • June 7, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • Immunosuppressants might lower Parkinson’s risk

    • June 1, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • Parkinson’s drug ALK4290 by Alkahest receives Grant for Preclinical Evaluation

    • May 31, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • EMA Validates MAA Submission for Acorda’s INBRIJA for Parkinson’s

    • May 31, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • Non Motor symptoms for Parkinson’s more common in women as compared to men, study states

    • May 27, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • Verge Genomics to generate Single Cell Data from Parkinson’s patients

    • May 22, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • Positive results for AFFITOPE® PD01A in Parkinson’s Disease Patients

    • May 20, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • Pre-market approval of INSIGHTEC’s device, for Parkinson’s disease, submitted to Japanese PMDA

    • May 20, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • 1
  • 2
  • 3
  • 4
Recent Posts
  • Unlocking the Benefits of SocialBI for Patient Engagement
  • Predictive Analytics in Healthcare
  • Business Intelligence and Analytics in the Pharma Industry
  • Role of Patient Insights in Building Strong Healthcare
  • Social Media Analytics in Healthcare

Contact Us

  • Indian Address: PharmaScroll Research and Consulting Private Limited, 91 Springboard, 4th floor, F948+W7, Laxmi Cyber City, Whitefields, Hyderabad, Telangana 500081
  • US address: 12 Self Ct, Wallingford CT 06492
  • +919311760222
  • enquiry@pharmascroll.com

Recent Tweets

Could not authenticate you.

Recent Posts

  • Unlocking the Benefits of SocialBI for Patient Engagement
  • Predictive Analytics in Healthcare
  • Business Intelligence and Analytics in the Pharma Industry

News Letter

© 2025 Copyright. All rights reserved